OXFENDAZOLE DEVELOPMENT GROUP

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2016

Legal Domicile

Principal Officer

R John Horton

Phone

4845573831

Tax Period

2025-01-01 to 2025-12-31

OXFENDAZOLE DEVELOPMENT GROUP, founded in 2016, is a micro nonprofit in the Medical Research sector that reported $9K in total revenue in fiscal year 2025. Revenue fell 63% from the prior year — a significant decline worth monitoring. Expenses of $227K exceeded revenue, resulting in a 2535% operating deficit.

Mission

The Oxfendazole Development Group is a 501c3 nonprofit organization formed and operated exclusively for charitable purposes specifically for the purpose of engaging in research and development of pharmaceutical treatments to help eliminate neglected tropical diseases NTDs and to facilitate access to such treatments for individuals in need.

Program Service Accomplishments

Program 1

Expenses: $225,315 Revenue: $0

scientific work toward the approval of oxfendazole for human use. nonclinical scientific studies.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2025)

Revenue Breakdown

Contributions & Grants $935

Program Service Revenue $0

Investment Income $7,672

Other Revenue $0

TOTAL REVENUE $8,607

Expense Breakdown

Grants Paid $0

Salaries & Benefits $0

Fundraising Expenses $0

Program Expenses $225,315

Other Expenses $226,784

TOTAL EXPENSES $226,784

Year-over-Year Comparison

	2025	2024	Change
Revenue	$8,607	$23,366	-0.6%
Expenses	$226,784	$851,968	-0.7%
Net Income	$-218,177	$-828,602	-0.7%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
R John Horton	President Board Member	4.00	Officer Director	$0	$0	$0
Ellen Codd	Treasurer Board Member	15.00	Officer Director	$0	$0	$0
Robert H Gilman	Board Member	2.00	Director	$0	$0	$0
Timothy Geary	Secretary Board member	3.00	Officer Director	$0	$0	$0
Javier Bustos	Board member	2.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$8,607	$226,784	$100,110	$-218,177
2024	$23,366	$851,968	$318,287	$-828,602
2023	$58,517	$604,664	$1,146,889	$-546,147
2022	$1,710,127	$42,614	$1,721,909	$1,667,513